Two major partnerships announced at JPM highlight an acceleration of AI investments across drug discovery and laboratory workflows. NVIDIA and Eli Lilly unveiled a $1 billion co‑innovation lab to integrate BioNeMo models with wet‑lab discovery, aiming to speed early discovery and in‑silico exploration of chemical and biological space. Separately, Thermo Fisher Scientific formalized a strategic collaboration with NVIDIA to embed AI across scientific instruments, lab infrastructure, and software to automate experiments and improve throughput. Both deals signal deepening ties between big tech and life‑science infrastructure providers.